Joel Mintz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joel Mintz has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Farzanna Haffizulla
Internal Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA
2 shared publications - Himanshu Arora
Department of Urology, Miller School of Medicine, University of Miami, Miami, USA
2 shared publications - Kyle S. Huntley
Medical student, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Ft. Lauderdale, Fla
2 shared publications - Waseem Wahood
Nova Southeastern University, Dr. Kiran C. Patel College of Medicine , Fort Lauderdale , United States of America
2 shared publications Alexandra Lee
Department of Medicine Duke University School of Medicine Durham North Carolina USA
1 shared publicationAli Farshchiansadegh
Northwestern University and the Shirley Ryan AbilityLab
1 shared publication
Latest Publications
- 23 July 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 53 (10) , e2076-e2081
Trends of Physical and Occupational Therapy Utilization in ICU Patients Undergoing Mechanical Ventilation in the United States: 2008–2021
BACKGROUND: Physical and occupational therapy (PT/OT) during invasive mechanical ventilation (IMV) may improve outcomes, however, utilization patterns are understudied. OBJECTIVES: Determine trends over time and by hospital in PT/OT utilization. DESIGN: Retrospective study. SETTING: Premier Healthcare Database hospitals (2008–2021). PATIENTS: Adults beginning IMV by hospitalization day 3 and receiving IMV continuously for 3–14 days. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome was PT/OT usage within the first 3 days of IMV (early PT/OT). Cochran-Armitage tests were used to evaluate unadjusted trends across discharge years. A multilevel multivariable logistic regression model was then created with discharge hospital as a random effect and clinical, sociodemographic, and hospital characteristics as covariables. The median odds ratio (mOR) was calculated to quantify the association of discharge hospital with PT/OT utilization. Across 814 hospitals, 1,228,909 early IMV hospitalizations were identified. Of those, 118,662 (9.7%) had early PT/OT. Frequency of early PT/OT rose from 2008 to 2019 (8.5–10.8%; p trend < 0.001) before declining in 2020 (9.5%) and 2021 (8.9%). Across hospitals, median early PT/OT usage was 5.4% (interquartile range, 2.9–11.0%). After multivariable adjustment, patients were increasingly more likely to get early PT/OT every year until 2016 (adjusted odds ratio [aOR] for 2016 vs. 2008, 1.52; 95% CI, 1.46–1.59). Use then remained relatively flat until 2020 when it began to decline (aOR for 2020, 1.23; 95% CI, 1.18–1.29 and aOR for 2021, 1.20; 95% CI, 1.15–1.26). The odds of receiving early PT/OT in higher use hospitals was nearly three-fold higher than in lower use hospitals (mOR, 2.82; 95% CI, 2.67–2.97). CONCLUSIONS: Early PT/OT usage rose during the early period, before declining significantly in 2020 and 2021. However, use in 2020 and 2021 remained higher than in 2008. Individual hospital of discharge was an important factor in determining who got PT/OT during IMV.
- 23 July 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 53 (10) , e2076-e2081
Trends of Physical and Occupational Therapy Utilization in ICU Patients Undergoing Mechanical Ventilation in the United States: 2008–2021
BACKGROUND: Physical and occupational therapy (PT/OT) during invasive mechanical ventilation (IMV) may improve outcomes, however, utilization patterns are understudied. OBJECTIVES: Determine trends over time and by hospital in PT/OT utilization. DESIGN: Retrospective study. SETTING: Premier Healthcare Database hospitals (2008–2021). PATIENTS: Adults beginning IMV by hospitalization day 3 and receiving IMV continuously for 3–14 days. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome was PT/OT usage within the first 3 days of IMV (early PT/OT). Cochran-Armitage tests were used to evaluate unadjusted trends across discharge years. A multilevel multivariable logistic regression model was then created with discharge hospital as a random effect and clinical, sociodemographic, and hospital characteristics as covariables. The median odds ratio (mOR) was calculated to quantify the association of discharge hospital with PT/OT utilization. Across 814 hospitals, 1,228,909 early IMV hospitalizations were identified. Of those, 118,662 (9.7%) had early PT/OT. Frequency of early PT/OT rose from 2008 to 2019 (8.5–10.8%; p trend < 0.001) before declining in 2020 (9.5%) and 2021 (8.9%). Across hospitals, median early PT/OT usage was 5.4% (interquartile range, 2.9–11.0%). After multivariable adjustment, patients were increasingly more likely to get early PT/OT every year until 2016 (adjusted odds ratio [aOR] for 2016 vs. 2008, 1.52; 95% CI, 1.46–1.59). Use then remained relatively flat until 2020 when it began to decline (aOR for 2020, 1.23; 95% CI, 1.18–1.29 and aOR for 2021, 1.20; 95% CI, 1.15–1.26). The odds of receiving early PT/OT in higher use hospitals was nearly three-fold higher than in lower use hospitals (mOR, 2.82; 95% CI, 2.67–2.97). CONCLUSIONS: Early PT/OT usage rose during the early period, before declining significantly in 2020 and 2021. However, use in 2020 and 2021 remained higher than in 2008. Individual hospital of discharge was an important factor in determining who got PT/OT during IMV.
- Open Access
Antibody Diversity in Cancer: Translational Implications and Beyond
Patients with cancer tend to develop antibodies to autologous proteins. This phenomenon has been observed across multiple cancer types, including bladder, lung, colon, prostate, and melanoma. These antibodies potentially arise due to induced inflammation or an increase in self-antigens. Studies focusing on antibody diversity are particularly attractive for their diagnostic value considering antibodies are present at an early diseased stage, serum samples are relatively easy to obtain, and the prevalence of antibodies is high even when the target antigen is minimally expressed. Conversely, the surveillance of serum proteins in cancer patients is relatively challenging because they often show variability in expression and are less abundant. Moreover, an antibody’s presence is also useful as it suggests the relative immunogenicity of a given antigen. For these reasons, profiling antibodies’ responses is actively considered to detect the spread of antigens following immunotherapy. The current review focuses on expanding the knowledge of antibodies and their diversity, and the impact of antibody diversity on cancer regression and progression.
Open AccessAntibody Diversity in Cancer: Translational Implications and Beyond
Patients with cancer tend to develop antibodies to autologous proteins. This phenomenon has been observed across multiple cancer types, including bladder, lung, colon, prostate, and melanoma. These antibodies potentially arise due to induced inflammation or an increase in self-antigens. Studies focusing on antibody diversity are particularly attractive for their diagnostic value considering antibodies are present at an early diseased stage, serum samples are relatively easy to obtain, and the prevalence of antibodies is high even when the target antigen is minimally expressed. Conversely, the surveillance of serum proteins in cancer patients is relatively challenging because they often show variability in expression and are less abundant. Moreover, an antibody’s presence is also useful as it suggests the relative immunogenicity of a given antigen. For these reasons, profiling antibodies’ responses is actively considered to detect the spread of antigens following immunotherapy. The current review focuses on expanding the knowledge of antibodies and their diversity, and the impact of antibody diversity on cancer regression and progression.
- Open Access
Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumorigenic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the level of production, the oxidative/reductive (redox) environment in which this radical is generated, the presence or absence of NO transduction elements, and the tumor microenvironment. Generally, there are four major categories of NO-based anticancer therapies: NO donors, phosphodiesterase inhibitors (PDE-i), soluble guanylyl cyclase (sGC) activators, and immunomodulators. Of these, NO donors are well studied, well characterized, and also the most promising. In this study, we review the current knowledge in this area, with an emphasis placed on the role of NO as an anticancer therapy and dysregulated molecular interactions during the evolution of cancer, highlighting the strategies that may aid in the targeting of cancer.
Open AccessCurrent Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumorigenic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the level of production, the oxidative/reductive (redox) environment in which this radical is generated, the presence or absence of NO transduction elements, and the tumor microenvironment. Generally, there are four major categories of NO-based anticancer therapies: NO donors, phosphodiesterase inhibitors (PDE-i), soluble guanylyl cyclase (sGC) activators, and immunomodulators. Of these, NO donors are well studied, well characterized, and also the most promising. In this study, we review the current knowledge in this area, with an emphasis placed on the role of NO as an anticancer therapy and dysregulated molecular interactions during the evolution of cancer, highlighting the strategies that may aid in the targeting of cancer.
- Open Access
- 8 December 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (12) , 449
Iron Therapeutics in Women’s Health: Past, Present, and Future
Iron plays a unique physiological role in the maintenance of homeostasis and the pathological outcomes of the female reproductive tract. The dual nature of elemental iron has created an evolutionary need to tightly regulate its biological concentration. The female reproductive tract is particularly unique due to the constant cycle of endometrial growth and shedding, in addition to the potential need for iron transfer to a developing fetus. Here, iron regulation is explored in a number of physiologic states including the endometrial lining and placenta. While iron dysregulation is a common characteristic in many women’s health pathologies there is currently a lack of targeted therapeutic options. Traditional iron therapies, including iron replacement and chelation, are common treatment options for gynecological diseases but pose long term negative health consequences; therefore, more targeted interventions directed towards iron regulation have been proposed. Recent findings show potential benefits in a therapeutic focus on ferritin-hepcidin regulation, modulation of reactive oxygen species (ROS), and iron mediated cell death (ferroptosis). These novel therapeutics are the direct result of previous research in iron’s complex signaling pathway and show promise for improved therapy, diagnosis, and prognosis in women’s health.
- 8 December 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (12) , 449
Open AccessIron Therapeutics in Women’s Health: Past, Present, and Future
Iron plays a unique physiological role in the maintenance of homeostasis and the pathological outcomes of the female reproductive tract. The dual nature of elemental iron has created an evolutionary need to tightly regulate its biological concentration. The female reproductive tract is particularly unique due to the constant cycle of endometrial growth and shedding, in addition to the potential need for iron transfer to a developing fetus. Here, iron regulation is explored in a number of physiologic states including the endometrial lining and placenta. While iron dysregulation is a common characteristic in many women’s health pathologies there is currently a lack of targeted therapeutic options. Traditional iron therapies, including iron replacement and chelation, are common treatment options for gynecological diseases but pose long term negative health consequences; therefore, more targeted interventions directed towards iron regulation have been proposed. Recent findings show potential benefits in a therapeutic focus on ferritin-hepcidin regulation, modulation of reactive oxygen species (ROS), and iron mediated cell death (ferroptosis). These novel therapeutics are the direct result of previous research in iron’s complex signaling pathway and show promise for improved therapy, diagnosis, and prognosis in women’s health.
- Open Access
- 7 December 2020
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (4) , 1099-1100
Validation of the Minimum Data Set Items on Falls and Injury in Two Long‐Stay Facilities
- 7 December 2020
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (4) , 1099-1100
Open AccessValidation of the Minimum Data Set Items on Falls and Injury in Two Long‐Stay Facilities
- 1 December 2020
- Published by Elsevier in Annals of Epidemiology
- Vol. 52, 104-105
Enforcement of Stay-at-home Orders Associated with Improved COVID-19 Population Outcomes
- 1 December 2020
- Published by Elsevier in Annals of Epidemiology
- Vol. 52, 104-105
Enforcement of Stay-at-home Orders Associated with Improved COVID-19 Population Outcomes
- Open Access
- 3 November 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (21) , 8115
Racial and Ethnic Disparities in COVID-19 Outcomes: Social Determination of Health
As of 18 October 2020, over 39.5 million cases of coronavirus disease 2019 (COVID-19) and 1.1 million associated deaths have been reported worldwide. It is crucial to understand the effect of social determination of health on novel COVID-19 outcomes in order to establish health justice. There is an imperative need, for policy makers at all levels, to consider socioeconomic and racial and ethnic disparities in pandemic planning. Cross-sectional analysis from COVID Boston University’s Center for Antiracist Research COVID Racial Data Tracker was performed to evaluate the racial and ethnic distribution of COVID-19 outcomes relative to representation in the United States. Representation quotients (RQs) were calculated to assess for disparity using state-level data from the American Community Survey (ACS). We found that on a national level, Hispanic/Latinx, American Indian/Alaskan Native, Native Hawaiian/Pacific Islanders, and Black people had RQs > 1, indicating that these groups are over-represented in COVID-19 incidence. Dramatic racial and ethnic variances in state-level incidence and mortality RQs were also observed. This study investigates pandemic disparities and examines some factors which inform the social determination of health. These findings are key for developing effective public policy and allocating resources to effectively decrease health disparities. Protective standards, stay-at-home orders, and essential worker guidelines must be tailored to address the social determination of health in order to mitigate health injustices, as identified by COVID-19 incidence and mortality RQs.
- 3 November 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (21) , 8115
Open AccessRacial and Ethnic Disparities in COVID-19 Outcomes: Social Determination of Health
As of 18 October 2020, over 39.5 million cases of coronavirus disease 2019 (COVID-19) and 1.1 million associated deaths have been reported worldwide. It is crucial to understand the effect of social determination of health on novel COVID-19 outcomes in order to establish health justice. There is an imperative need, for policy makers at all levels, to consider socioeconomic and racial and ethnic disparities in pandemic planning. Cross-sectional analysis from COVID Boston University’s Center for Antiracist Research COVID Racial Data Tracker was performed to evaluate the racial and ethnic distribution of COVID-19 outcomes relative to representation in the United States. Representation quotients (RQs) were calculated to assess for disparity using state-level data from the American Community Survey (ACS). We found that on a national level, Hispanic/Latinx, American Indian/Alaskan Native, Native Hawaiian/Pacific Islanders, and Black people had RQs > 1, indicating that these groups are over-represented in COVID-19 incidence. Dramatic racial and ethnic variances in state-level incidence and mortality RQs were also observed. This study investigates pandemic disparities and examines some factors which inform the social determination of health. These findings are key for developing effective public policy and allocating resources to effectively decrease health disparities. Protective standards, stay-at-home orders, and essential worker guidelines must be tailored to address the social determination of health in order to mitigate health injustices, as identified by COVID-19 incidence and mortality RQs.
- 29 September 2020
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 28 (9) , 670-679
Tele-ophthalmology for age-related macular degeneration during the COVID-19 pandemic and beyond
Introduction: COVID-19 has disrupted how ophthalmic practice is conducted worldwide. One patient population that may suffer from poor outcomes during the pandemic are those with age-related macular degeneration (AMD). Many practices are performing some form of tele-ophthalmology services for their patients, and guidance is needed on how to maintain continuity of care amongst patients with AMD using tele-ophthalmology. Methods: A literature search was conducted, ending 1 August 2020, to identify AMD outcomes and telecare management strategies that could be used during the COVID-19 pandemic Results: 237 total articles were retrieved, 56 of which were included for analysis. Four American Academy of Ophthalmology and Center for Disease Control web resources were also included. Discussion: Risk-stratification models have been developed that let providers readily screen existing patients for their future risk of neovascular AMD (nAMD). When used with at-home monitoring devices to detect nAMD, providers may be able to determine who should be contacted via tele-ophthalmology for screening. Telemedicine triage can be used for new complaints of vision loss to determine who should be referred to a retinal specialist for management of suspected nAMD. To increase access and provider flexibility, smartphone fundus photography images sent to a centralized tele-ophthalmology service can aid in the detection of nAMD. Considerations should also be made for COVID-19 transmission, and tele-ophthalmology can be used to screen patients for the presence of COVID-19 prior to in-person office visits. Tele-ophthalmology has additional utility in connecting with nursing home, rural, and socioeconomically disadvantaged patients in the post-pandemic period.
- 29 September 2020
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 28 (9) , 670-679
Tele-ophthalmology for age-related macular degeneration during the COVID-19 pandemic and beyond
Introduction: COVID-19 has disrupted how ophthalmic practice is conducted worldwide. One patient population that may suffer from poor outcomes during the pandemic are those with age-related macular degeneration (AMD). Many practices are performing some form of tele-ophthalmology services for their patients, and guidance is needed on how to maintain continuity of care amongst patients with AMD using tele-ophthalmology. Methods: A literature search was conducted, ending 1 August 2020, to identify AMD outcomes and telecare management strategies that could be used during the COVID-19 pandemic Results: 237 total articles were retrieved, 56 of which were included for analysis. Four American Academy of Ophthalmology and Center for Disease Control web resources were also included. Discussion: Risk-stratification models have been developed that let providers readily screen existing patients for their future risk of neovascular AMD (nAMD). When used with at-home monitoring devices to detect nAMD, providers may be able to determine who should be contacted via tele-ophthalmology for screening. Telemedicine triage can be used for new complaints of vision loss to determine who should be referred to a retinal specialist for management of suspected nAMD. To increase access and provider flexibility, smartphone fundus photography images sent to a centralized tele-ophthalmology service can aid in the detection of nAMD. Considerations should also be made for COVID-19 transmission, and tele-ophthalmology can be used to screen patients for the presence of COVID-19 prior to in-person office visits. Tele-ophthalmology has additional utility in connecting with nursing home, rural, and socioeconomically disadvantaged patients in the post-pandemic period.
- 16 October 2018
- Published by Springer Nature
- p. 1034-1038
Designing Visual Feedback to Reshape Muscle Coordination
- 16 October 2018
- Published by Springer Nature
- p. 1034-1038
Designing Visual Feedback to Reshape Muscle Coordination